162 related articles for article (PubMed ID: 19513073)
1. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.
de Graeff P; Crijns AP; de Jong S; Boezen M; Post WJ; de Vries EG; van der Zee AG; de Bock GH
Br J Cancer; 2009 Jul; 101(1):149-59. PubMed ID: 19513073
[TBL] [Abstract][Full Text] [Related]
2. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Seidal T
Int J Gynecol Cancer; 2001; 11(2):119-29. PubMed ID: 11328410
[TBL] [Abstract][Full Text] [Related]
3. Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis.
Wang S; Zheng G; Chen L; Xiong B
Asian Pac J Cancer Prev; 2011; 12(6):1417-23. PubMed ID: 22229170
[TBL] [Abstract][Full Text] [Related]
4. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
Nijman HW; Kenemans P; Poort-Keesom RJ; Verstraeten RA; Mensdorff-Pouilly S; Verheijen RH; Melief CJ; Hilgers J; Meijer CJ
Eur J Obstet Gynecol Reprod Biol; 1999 Apr; 83(2):201-6. PubMed ID: 10391533
[TBL] [Abstract][Full Text] [Related]
5. Lack of effects of HER-2/neu on prognosis in colorectal cancer: a meta-analysis.
Han J; Meng QY; Liu X; Xi QL; Zhuang QL; Wu GH
Asian Pac J Cancer Prev; 2014; 15(14):5551-6. PubMed ID: 25081663
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
8. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
[TBL] [Abstract][Full Text] [Related]
9. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.
Cloven NG; Kyshtoobayeva A; Burger RA; Yu IR; Fruehauf JP
Gynecol Oncol; 2004 Jan; 92(1):160-6. PubMed ID: 14751152
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
Engelsen IB; Stefansson IM; Beroukhim R; Sellers WR; Meyerson M; Akslen LA; Salvesen HB
Int J Oncol; 2008 Feb; 32(2):307-16. PubMed ID: 18202752
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.
García-Velasco A; Mendiola C; Sánchez-Muñoz A; Ballestín C; Colomer R; Cortés-Funes H
Clin Transl Oncol; 2008 Jun; 10(6):367-71. PubMed ID: 18558584
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
15. Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr--a survival study.
Layfield LJ; Thompson JK; Dodge RK; Kerns BJ
J Surg Oncol; 1995 May; 59(1):21-7. PubMed ID: 7745972
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 and HER2/Neu in Kenyan Women With Primary Ovarian Carcinoma.
Mutuiri AP; Nzioka A; Busarla SV; Sayed S; Moloo Z
Int J Gynecol Pathol; 2016 Nov; 35(6):537-543. PubMed ID: 26825003
[TBL] [Abstract][Full Text] [Related]
17. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
[TBL] [Abstract][Full Text] [Related]
18. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Gupta D; Shidham V; Holden J; Layfield L
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]